Daniel Joe Lovell, ACR 2020 – Results from the Ongoing Phase IV PRCSG/PRINTO Registry
We caught up with Daniel Joe Lovell (University of Cincinnati School of Medicine, Cincinnati, OH, USA) to discuss the effectiveness of abatacept in juvenile idiopathic arthritis categories. The abstract ‘Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry’ (ABSTRACT NUMBER: 0714) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What is the evidence and rationale for the use of abatacept in the treatment of juvenile idiopathic arthritis (JIA)? (0:25)
- Where does abatacept fit into the treatment paradigm for JIA? (2:05)
- What were the aims and design of the PRCSG/PRINTO JIA abatacept phase IV registry? (3:12)
- What were the strengths and limitations of the study? (4:48)
- What have been the findings to date and how will they inform future clinical practice? (6:56)
Disclosures: D. J. Lovell has served on speakers’ bureaus for Bristol-Myers Squibb Company, Genentech and Wyeth; has received consulting fees from Takeda and Celgene; and has served on data and safety monitoring boards for Forest Research and the National Institutes of Health-NIAMS; Cincinnati Children’s Hospital Medical Center has received consulting fees from Abbott, AbbVie, AstraZeneca, Bristol-Myers Squibb Company, Centocor, F. Hoffman La-Roche, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Roche, UBC, and Xoma for the work of D. J. Lovell; and has received research funding from the National Institute of Child Health and Human Development.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Rheumatic Diseases
Machine-learning models as predictors of fractures in osteoporosis: Giovanni Adami, WCO-IOF-ESCEO 2023
In this study a machine-learning approach was investigated over two years to determine the efficacy of fracture risk prediction in osteoporosis. touchIMMUNOLOGY were delighted to speak with Dr. Giovanni Adami (University of Verona, Verona, Italy) to discuss the machine-learning models already available for screening osteoporosis and their limitations, the risk factors used as predictors of […]
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!